9-Oct-2026
Globe Newswire (Thu, 17-Sep 8:05 AM ET)
Globe Newswire (Thu, 13-Aug 8:30 AM ET)
Globe Newswire (Tue, 11-Aug 8:30 AM ET)
Globe Newswire (Thu, 30-Jul 8:30 AM ET)
Cingulate Secures U.S. Patent for CTx-1301, Paving Way for Next-Gen ADHD Treatments
Market Chameleon (Tue, 16-Jun 4:51 AM ET)
Cingulate Bolsters Cash Position to $25.9 Million and Scales Up for CTx-1301 Launch Readiness
Market Chameleon (Thu, 14-May 6:13 AM ET)
Cingulate Advances ADHD Program as CTx-1301 Patents and Regulatory Milestones Build Momentum
Market Chameleon (Wed, 18-Mar 4:58 AM ET)
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
Cingulate trades on the NASDAQ stock market under the symbol CING.
As of October 9, 2026, CING stock price climbed to $4.89 with 27,814 million shares trading.
CING has a beta of -0.18, meaning it tends to be less sensitive to market movements. CING has a correlation of 0.00 to the broad based SPY ETF.
CING has a market cap of $71.11 million. This is considered a Micro Cap stock.
In the last 3 years, CING traded as high as $156.00 and as low as $1.80.
The top ETF exchange traded funds that CING belongs to (by Net Assets): VTI, VXF, IWC.
CING has underperformed the market in the last year with a return of +12.4%, while the SPY ETF gained +17.1%. In the last 3 month period, CING fell short of the market, returning -1.2%, while SPY returned +3.8%. However, in the most recent 2 weeks CING has outperformed the stock market by returning +1.2%, while SPY returned +0.9%.
CING support price is $4.68 and resistance is $5.08 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CING shares will trade within this expected range on the day.
